NCT06765317

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Optimizing Frontline Therapy for DLBCL in Older Adults: A GLOfitamab-based, Response-adapted, Window-stYle Study (GLORY)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 65 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).

Conditions

• Diffuse Large B Cell Lymphoma (DLBCL)
• High Grade B Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Glofitamab	C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks
DRUG	Polatuzumab	1.8 mg/kg iv C1D1 onwards, every 3 weeks
DRUG	Rituximab	375 mg/m2 iv D1
DRUG	Cyclophosphamide	400 mg/m2 iv D1
DRUG	Doxorubicin	25 mg/m2 iv D1
DRUG	Obinutuzumab:	1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose

Timeline

• Start date: 2025-01-16
• Primary completion: 2028-01-01
• Completion: 2028-01-01
• First posted: 2025-01-09
• Last updated: 2025-11-26

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study